Agios Pharmaceuticals Inc

Financials

Total assets 852.95 M1.44 B1.24 B937.12 M1.66 B1.3 B Total liabilities 453.45 M145.76 M137.9 M126.1 M122.24 M104.11 M Total equity 399.5 M1.29 B1.1 B811.02 M1.54 B1.19 B Total liabilities & shareholders' equities 852.95 M1.44 B1.24 B937.12 M1.66 B1.3 B Total debt —————— Net debt ——————

Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

AGIO

Financials

Agios Pharmaceuticals Inc

Nouvelles

Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

Truist Securities relève l’objectif de prix de l’action Agios Pharma à 39€ suite aux avancées de son pipeline

Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress

Le BPA de Agios Pharm a dépassé les attentes de 0,09$, le CA a surpassé les prévisions

Agios Pharm earnings beat by $0.09, revenue topped estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharma s’apprête à publier ses résultats en plein déploiement de son médicament contre la thalassémie

Agios Pharm set to report earnings amid thalassemia drug rollout

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Williams to Report Q4 Earnings: What Surprise Awaits Investors?

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AGIO) 2026-01-14